Source: Virtual Congress 2020 – Scientific advances in airway pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Kreideweiss (Biberach, Germany), A. Schuler-Metz (Biberach, Germany), C. Gnamm (Biberach, Germany), S. Peters (Biberach, Germany), T. Oost (Biberach, Germany). In vitro and in vivo characterisation of the novel neutrophil elastase inhibitor BI 1323495. 3303

Member's Comments

No comment yet.

Related content which might interest you: In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: Lung Science Conference 2015 Year: 2015 In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE) Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010 Roflumilast inhibits leukocyte cell interactions in vivo Source: Eur Respir J 2006; 28: Suppl. 50, 224s Year: 2006 The effect of recombinant Il-8 on eosinophil migration in vitro and in vivo Source: Eur Respir J 2002; 20: Suppl. 38, 382s Year: 2002 Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 An innovative high sensitivity tool for active neutrophil elastase quantification Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Effects of N-acetylcysteine and salbutamol on neutrophil migration and release of interleukin-8 and elastase by neutrophils in vitro Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004 The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 Neutrophil activity assessed using a novel serological marker of human neutrophil elastase degraded calprotectin is elevated in patients with COPD or IPF Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery Year: 2021 Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS Source: Annual Congress 2012 - How to use technology to provide better critical care Year: 2012 Zaphirlukast inhibits in vitro the respiratory burst of human neutrophils Source: Eur Respir J 2001; 18: Suppl. 33, 79s Year: 2001 Effect of human neutrophil proteases on ex vivo small airway function Source: Annual Congress 2013 –Stress responses and T-cell behaviour in the lung Year: 2013 ²Classical vasodilators² inhibit the recruitment of polymorphonuclear leukocytes in vitro Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 Evidence that cathepsin G counteracts the profibrotic effects of neutrophil elastase following lung injury Source: Eur Respir J 2001; 18: Suppl. 33, 181s Year: 2001 Investigating optimal sputum processing methods for active neutrophil elastase quantification Source: International Congress 2017 – Techniques in biomarker selection Year: 2017